Insider Buying: Hemostemix Inc. (CVE:HEM) Director Purchases 200,000 Shares of Stock

Hemostemix Inc. (CVE:HEM - Get Free Report) Director Peter Alan Lacey purchased 200,000 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was bought at an average price of C$0.15 per share, with a total value of C$30,000.00.

Peter Alan Lacey also recently made the following trade(s):

• On Wednesday, February 26th, Peter Alan Lacey sold 96,464 shares of Hemostemix stock. The shares were sold at an average price of C$0.18, for a total transaction of C$16,881.20.

Hemostemix Stock Performance

Shares of HEM opened at C$0.13 on Tuesday. The company has a 50-day simple moving average of C$0.22 and a 200-day simple moving average of C$0.13. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The company has a market capitalization of C$18.22 million, a PE ratio of -3.64 and a beta of 0.20. Hemostemix Inc. has a 52-week low of C$0.04 and a 52-week high of C$0.43.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

See Also

• Five stocks we like better than Hemostemix
• The Role Economic Reports Play in a Successful Investment Strategy
• How to Protect Your Portfolio When Inflation Is Rising
• About the Markup Calculator
• 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
• How to start investing in penny stocks
• Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.

More From MarketBeat

BITCOIN

Did you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....

Awesomely, LLC | Sponsored

7 Best Growth Stocks for the Next 10 Years

If you're somewhat new to investing, the term “growth stocks" may be confusing. After all, don't you wan...

MarketBeat

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse

Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...

Priority Gold | Sponsored

Profit Without Panic: 7 ETFs to Diversify Your Portfolio

Many investors find fund investing to be a sound alternative to the ups and downs that come with owning...

MarketBeat

Trump’s Final Plan

Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...

Porter & Company | Sponsored

7 Large-Cap Stocks Poised for Strong, Steady Gains in 2025

Growth stocks have outperformed value stocks in 2024 and are likely to continue to do so in 2025. Two reason...

MarketBeat

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...

Weiss Ratings | Sponsored

20 "Past Their Prime" Stocks to Dump From Your Portfolio

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ...

MarketBeat